SASLT guidelines: Update in treatment of Hepatitis C virus infection

Alghamdi, Abdullah S; Alghamdi, Mohammed; Sanai, Faisal M.; Alghamdi, Hamdan S.; Abaalkhail, Faisal; Alswat, Khalid; Babatin, Mohamed; Alqutub, Adel; Altraif, Ibrahim; Al-Faleh, Faleh Z.

doi:10.4103/1319-3767.188067

Cited by 20 publications

(23 citation statements)

References 156 publications

(147 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of hepatitis C virus (HCV) is approximately 1%-2%, with a predominance of genotype 4 infection, and HCV is currently the leading indication for LT. (4) The indications for LT in KSA are shifting from viral-induced liver disease to nonalcoholic fatty liver-related cirrhosis. (3) Nonalcoholic steatohepatitis (NASH)-related liver disease is a rising global concern due to the obesity epidemic.…”

Section: Current Demand For and Means Of Access To Liver Transplantationmentioning

confidence: 99%

Liver transplantation in the Kingdom of Saudi Arabia

Sebayel¹,

Abaalkhail²,

Abbad³

et al. 2017

Liver Transpl

View full text Add to dashboard Cite

The first liver transplantation (LT) in Saudi Arabia was performed in 1991; however, it was not until 1994 that the first structured LT program was launched. Until 1997, all LTs in the Kingdom of Saudi Arabia (KSA) were deceased donor liver transplantations. Programs performing LTs needed the authorization of the Saudi Center for Organ Transplantation (SCOT), which provides the essential support for organ procurement and allocation as well as regulatory support for organ transplantation in the country. Currently, there are 4 LT centers in the KSA. Three centers are in Riyadh, the capital city of KSA, and 1 is in the city of Dammam in the Eastern province. Pediatric living donor liver transplantation (LDLT) began in 1997, while the adult LDLT program started 4 years later in 2001. Currently, more than 2000 LTs have been performed by the 4 centers in the KSA. Over 50% of those were performed at King Faisal Specialist Hospital and Research Center in Riyadh. The outcomes of these transplants have been comparable with the international standards. The aim of this review is to provide an overview of LT in KSA. Liver Transplantation 23 1312-1317 2017 AASLD.

show abstract

Section: Current Demand For and Means Of Access To Liver Transplantationmentioning

confidence: 99%

Liver transplantation in the Kingdom of Saudi Arabia

Sebayel¹,

Abaalkhail²,

Abbad³

et al. 2017

Liver Transpl

View full text Add to dashboard Cite

show abstract

“…Chronic hepatitis C virus (HCV) infection is a major health problem worldwide and is a leading cause of liver‐related morbidity and mortality . Worldwide genotype (GT) 4 accounts for about 15 million infections and is the commonest type in the Middle‐Eastern region . HCV is more prevalent among patients with chronic kidney disease (CKD) than among those without the disease .…”

Section: Introductionmentioning

confidence: 99%

“…However, the treatment options are limited in patients with CKD. In severe (stage 4 or 5) CKD, co‐formulated ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) is approved for a 12‐week treatment regimen in GT4 and in combination with dasabuvir (DSV) for GT1a/b, with or without RBV …”

Section: Introductionmentioning

confidence: 99%

“…1 Worldwide genotype (GT) 4 accounts for about 15 million infections and is the commonest type in the Middle-Eastern region. 2,3 HCV is more prevalent among patients with chronic kidney disease (CKD) than among those without the disease. 4,5 Infected patients are more likely to progress to end-stage kidney disease.…”

Section: Introductionmentioning

confidence: 99%

“…In severe (stage 4 or 5) CKD, coformulated ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) is approved for a 12-week treatment regimen in GT4 and in combination with dasabuvir (DSV) for GT1a/b, with or without RBV. 3,9 In the RUBY-I and II trials, observed rates of SVR12 were 90% (18/20) and 100% (13/13), respectively, in treatment-naïve GT1 patients without cirrhosis. 9,10 Data on GT4 are very limited.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1–infected patients with severe chronic kidney disease

Sanai

Alghamdi

Afghani

et al. 2018

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

Beyond genotype‐4: Direct‐acting antiviral agents in patients with chronic hepatitis C infection from the Eastern Province of Saudi Arabia

Ismail

2024

Health Science Reports

View full text Add to dashboard Cite

Background and AimsDirect‐acting antiviral agents (DAAs) have revolutionized the treatment of patients with chronic hepatitis C virus (HCV) infection, resulting in a high sustained virologic response (SVR) rate. However, the published data from the Eastern Province of Saudi Arabia are limited to small patient groups and specific DAAs used for patients with genotype‐4.(GT‐4). This study aimed to investigate the effectiveness and safety of DAAs for treating HCV infection in Saudi Arabia in a real‐life setting.MethodsThis retrospective study from January 2015 to December 2019 included all HCV‐infected patients who received DAAs at a tertiary university hospital in Saudi Arabia. Baseline characteristics and laboratory data were collected from health records, including HCV RNA level, genotype, and presence of liver cirrhosis or steatosis. The primary outcome was undetectable HCV RNA at 12 weeks posttreatment (SVR12). Results were stratified based on different DAAs and HCV genotypes. Treatment‐related adverse events were recorded. Statistical analyses were performed using SPSS version 25.0.ResultsOf the 117 patients included, 43.2% had advanced fibrosis or cirrhosis, and the majority (90.6%) were treatment‐naïve. The mean age was 50.1 ± 15.5 years, with 57.3% females. The most common genotype was GT‐4 (44.4%), followed by GT‐1 (40.2%). Most patients (64.3%) received sofosbuvir and daclatasvir ± ribavirin, while the remaining patients received various DAAs. Overall, 98.3% of the patients achieved SVR12. The therapy was well tolerated, with fatigue and headache being the most common side effects.ConclusionsTreatment with DAAs is highly effective across different genotypes and various DDA regimens in the real world for treating HCV infection in the Eastern Province of Saudi Arabia, contributing to improved patient outcomes and the overall goal of HCV elimination.

show abstract

SASLT guidelines: Update in treatment of Hepatitis C virus infection

Cited by 20 publications

References 156 publications

Liver transplantation in the Kingdom of Saudi Arabia

Liver transplantation in the Kingdom of Saudi Arabia

High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1–infected patients with severe chronic kidney disease

Beyond genotype‐4: Direct‐acting antiviral agents in patients with chronic hepatitis C infection from the Eastern Province of Saudi Arabia

Contact Info

Product

Resources

About